Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma gmbh - folic acid, ferroglycin sulfate complex - kapseli, kova - ferro-aminohappokompleksi

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma oy finland - cetirizini dihydrochloridum,pseudoephedrini hydrochloridum - säädellysti vapauttava tabletti - 5 mg / 120 mg - pseudoefedriini, yhdistelmävalmisteet

Euroopan unioni - suomi - EMA (European Medicines Agency)

ucb pharma ltd - natriumoksibaatti - cataplexy; narcolepsy - muut hermoston huumeet - narkolepsian hoito katapleksiaan aikuispotilailla.

Euroopan unioni - suomi - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporoosi - lääkkeet luusairauksien hoitoon - evenity on tarkoitettu vaikean osteoporoosin postmenopausaalisilla naisilla, joilla on suuri riski saada murtuma.

Euroopan unioni - suomi - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressantit - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - epilepsialääkkeet, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma sa - rotigotinum - depotlaastari - 2 mg / 24 tuntia - rotigotiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma sa - rotigotinum - depotlaastari - 4 mg / 24 tuntia - rotigotiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma sa - rotigotinum - depotlaastari - 6 mg / 24 tuntia - rotigotiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb pharma sa - rotigotinum - depotlaastari - 8 mg / 24 tuntia - rotigotiini